North Island
Southern Island
The University of Oxford announced today that it is resuming a trial for a coronavirus vaccine to be presented with pharmaceutical company AstraZeneca, a resolution that occurs days after the test was discontinued due to an informed side effect on a British patient.
In a statement, the university showed the restart of all its test sites in the UK after regulators gave the go-ahead after the break.
“The indefinite review procedure has come to an end and following the recommendations of the indefinite protection review committee and uk regulator MHRA will resume trials in the UK,” he said.
The vaccine being developed through Oxford and AstraZeneca is widely known as one of the top tough competitors among the dozens of coronavirus vaccines in trial stages around the world.
UK Health Secretary Matt Hancock welcomed the reboot and said in a tweet it was “good news for everyone” that the test “is working again. “
The university said that in giant trials like this “some participants are expected to feel insecure and each case will have to be thoroughly evaluated to ensure a full protection assessment. “
He said around 18,000 international people have won their vaccine in Britain, Brazil and South Africa. Approximately 30,000 volunteers are being recruited in the United States.
Although Oxford reveals data on the patient’s illness due to the confidentiality of the participants, an AstraZeneca spokesperson said this week that a woman had developed severe neurological symptoms that caused the break. Specifically, the woman developed symptoms consistent with transverse myelitis, a rare disease. inflammation of the spinal cord.
The university presses that it is “committed to protecting our participants and the criteria for conduct in our studies and will continue to monitor protection closely. “
Disruptions in drug testing are and the suspension of transitoryness caused a sharp drop in the percentage value of AstraZeneca after Wednesday’s announcement.
The Oxford-AstraZeneca test was already suspended in July for several days after a player developed neurological symptoms that turned out to be an undiagnosed case of sclerosis that researchers declared unrelated to the vaccine.
During the third and final level of testing, researchers look for any symptoms of imaginable side effects that may not have been detected in previous research with patients.
Because of their giant size, studies are the most important testing phase for finding less common side effects and identifying safety.
Trials also compare efficacy by tracking who converts and who does not among patients receiving the vaccine and those receiving a fake vaccine.
Dr. Charlotte Summers, senior professor of extensive care medicine at the University of Cambridge, said the breakup is a sign that the Oxford team prioritizes protection issues, but that it leads to “a lot of unnecessary speculation. “
“To combat the Covid-19 global pandemic, we want to expand vaccines and treatments that others feel comfortable using, so it’s important for the public confidence that we stick to the evidence and don’t draw conclusions until the data becomes available. “she said.
Scientists and stakeholders around the world, as well as experts from the World Health Organization, have sought to involve expectations of imminent progress for coronavirus vaccines, noting that vaccine trials are rarely simple.
Italian Health Minister Roberto Speranza welcomed the resumption of the vaccine trial, but warned that caution is still needed.
“Science is in paints to give effective remedies and vaccines globally,” he said. “In the meantime, the key remains our behavior. “
Italy, which is point 0 of the epidemic in Europe, is one of the leading countries investing in the AstraZeneca vaccine.
Two other vaccines are in the latter large stages in the United States, one manufactured through Moderna Inc. and the other through Pfizer and BioNTech from Germany.